1. Home
  2. AZTR vs BYAH Comparison

AZTR vs BYAH Comparison

Compare AZTR & BYAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.21

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Logo Park Ha Biological Technology Co. Ltd. Ordinary Shares

BYAH

Park Ha Biological Technology Co. Ltd. Ordinary Shares

N/A

Current Price

$1.07

Market Cap

3.3M

ML Signal

N/A

Company Overview

Basic Information
Metric
AZTR
BYAH
Founded
2014
2016
Country
United States
China
Employees
N/A
41
Industry
Biotechnology: Pharmaceutical Preparations
Package Goods/Cosmetics
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.5M
3.3M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
AZTR
BYAH
Price
$0.21
$1.07
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
2.5M
19.0K
Earning Date
05-12-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
5.06
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.05
52 Week High
$1.40
$2.77

Technical Indicators

Market Signals
Indicator
AZTR
BYAH
Relative Strength Index (RSI) 44.82 50.00
Support Level $0.15 $0.93
Resistance Level $0.23 $2.77
Average True Range (ATR) 0.01 0.08
MACD -0.00 0.00
Stochastic Oscillator 3.99 69.03

Price Performance

Historical Comparison
AZTR
BYAH

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

About BYAH Park Ha Biological Technology Co. Ltd. Ordinary Shares

Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales, and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha, in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complementary after-sales beauty services in its physical stores.

Share on Social Networks: